MARKET

TECH

TECH

Bio-Techne
NASDAQ

Real-time Quotes | Nasdaq Last Sale

528.82
-5.53
-1.03%
Closed 16:44 09/20 EDT
OPEN
525.25
PREV CLOSE
534.35
HIGH
535.64
LOW
518.06
VOLUME
401.28K
TURNOVER
--
52 WEEK HIGH
540.00
52 WEEK LOW
228.67
MARKET CAP
20.75B
P/E (TTM)
152.47
1D
5D
1M
3M
1Y
5Y
Bio-Techne Corporation's (NASDAQ:TECH) Stock Is Going Strong: Have Financials A Role To Play?
Most readers would already be aware that Bio-Techne's (NASDAQ:TECH) stock increased significantly by 21% over the past...
Simply Wall St. · 18h ago
Trend Aggregation US ETF Buys Moderna Inc, Lam Research Corp, , Sells Keurig Dr Pepper Inc, ...
GuruFocus News · 18h ago
Brown Capital Management Small Company Fund Buys 10x Genomics Inc, Smartsheet Inc, Alarm. ...
GuruFocus News · 2d ago
Bio-Techne's Plan to Double Sales in Five Years Underpinned by Strong Market Positioning, KeyBanc Says
MT Newswires · 5d ago
Keybanc Upgrades Bio-Techne to Overweight, Announces $600 Price Target
Keybanc analyst Paul Knight upgrades Bio-Techne (NASDAQ:TECH) from Sector Weight to Overweight and announces $600 price target.
Benzinga · 6d ago
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 6d ago
Bio-Techne Launches ExCellerate™ iPSC Expansion Medium
Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium i...
PR Newswire · 09/14 11:00
Director Of Bio-Techne Trades $4.80 Million In Company Stock
Randolph C Steer, Director at Bio-Techne (NASDAQ:TECH), made a large buy and sell of company shares on September 7, according to a new SEC filing.
Benzinga · 09/09 22:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TECH. Analyze the recent business situations of Bio-Techne through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TECH stock price target is 549.60 with a high estimate of 600.00 and a low estimate of 490.00.
EPS
Institutional Holdings
Institutions: 644
Institutional Holdings: 40.20M
% Owned: 102.45%
Shares Outstanding: 39.24M
TypeInstitutionsShares
Increased
153
3.01M
New
82
336.67K
Decreased
174
2.59M
Sold Out
38
368.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
Robert Baumgartner
President/Chief Executive Officer/Director
Charles Kummeth
Chief Financial Officer/Executive Vice President - Finance
James Hippel
Corporate Executive
David Eansor
Corporate Executive
Kim Kelderman
Executive Vice President/General Counsel/Secretary
Brenda Furlow
Independent Director
Julie Bushman
Independent Director
John Higgins
Independent Director
Joseph Keegan
Independent Director
Roeland Nusse
Independent Director
Alpna Seth
Independent Director
Randolph Steer
Independent Director
Rupert Vessey
Declaration Date
Dividend Per Share
Ex-Div Date
08/05/2021
Dividend USD 0.32
08/13/2021
05/06/2021
Dividend USD 0.32
05/14/2021
02/02/2021
Dividend USD 0.32
02/11/2021
11/05/2020
Dividend USD 0.32
11/13/2020
08/04/2020
Dividend USD 0.32
08/17/2020
04/30/2020
Dividend USD 0.32
05/08/2020
02/04/2020
Dividend USD 0.32
02/13/2020
10/29/2019
Dividend USD 0.32
11/07/2019
08/06/2019
Dividend USD 0.32
08/15/2019
04/30/2019
Dividend USD 0.32
05/09/2019
02/05/2019
Dividend USD 0.32
02/14/2019
--
Dividend USD 0.32
11/08/2018
--
Dividend USD 0.32
08/16/2018
--
Dividend USD 0.32
05/11/2018
--
Dividend USD 0.32
02/15/2018
--
Dividend USD 0.32
11/09/2017
--
Dividend USD 0.32
08/16/2017
--
Dividend USD 0.32
05/17/2017
--
Dividend USD 0.32
02/15/2017
10/31/2016
Dividend USD 0.32
11/09/2016
  • All
  • Financials
  • Insiders
More
About TECH
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.